Literature DB >> 21573737

TD-12 workshop report: characterization of monoclonal antibodies to neuron-specific enolase.

Elisabeth Paus1, Klaus Hirzel, Maria Lidqvist, Matti Höyhtyä, David J Warren.   

Abstract

Twelve antibodies to neuron-specific enolase (NSE) have been evaluated by four working groups. Human brain γγ-enolase, neuroblastoma-derived αγ-enolase, and recombinant γγ-enolase were used to determine antibody specificity and binding kinetics. All antibodies were found to be specific for the γ-isoform. It was possible to assign 11 of the antibodies to at least five epitope groups based on cross-inhibition experiments, QCM and SPR technology, and immunoassay combinations. Antibodies 9601 and 9602 showed the highest affinity for both native and recombinant γγ-enolase. Immunometric assays for both γγ- and αγ-enolase could be made by pairing 9601 with most of the other ISOBM antibodies. Antibodies differed in their ability to recognize native αγ-enolase, native γγ-enolase, and recombinant γγ-enolase. Some immunometric assay combinations appear to favor the detection of heterodimeric αγ-enolase over the homodimeric γγ-enolase. Although the majority of the antibodies failed to detect human NSE or recombinant NSE in Western blots, mAb 9601 recognized both, while E17 and 18E5 were specific for human NSE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573737     DOI: 10.1007/s13277-011-0184-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  Performance characteristics of seven neuron-specific enolase assays.

Authors:  Petr Stern; Vladimir Bartos; Jana Uhrova; Drahomira Bezdickova; Zdislava Vanickova; Vojtech Tichy; Kveta Pelinkova; Richard Prusa; Tomas Zima
Journal:  Tumour Biol       Date:  2007-01-26

2.  Serum neuron-specific/nonneuronal enolase ratio in the diagnosis of neuroblastomas.

Authors:  J L Viallard; F Tiget; O Hartmann; J Lemerle; F Demeocq; G Malpuech; B Dastugue
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

3.  Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.

Authors:  O C Burghuber; B Worofka; G Schernthaner; N Vetter; M Neumann; R Dudczak; R Kuzmits
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

4.  Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.

Authors:  J A Bonner; J A Sloan; K M Rowland; G G Klee; J W Kugler; J A Mailliard; M Wiesenfeld; J E Krook; A W Maksymiuk; E G Shaw; R S Marks; E A Perez
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

Review 5.  Clinical biochemistry of neuron specific enolase.

Authors:  E Kaiser; R Kuzmits; P Pregant; O Burghuber; W Worofka
Journal:  Clin Chim Acta       Date:  1989-07-31       Impact factor: 3.786

6.  Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles.

Authors:  E Paus; K Nustad
Journal:  Clin Chem       Date:  1989-10       Impact factor: 8.327

7.  Expression, purification and the 1.8 angstroms resolution crystal structure of human neuron specific enolase.

Authors:  Geqing Chai; John M Brewer; Leslie L Lovelace; Takashi Aoki; Wladek Minor; Lukasz Lebioda
Journal:  J Mol Biol       Date:  2004-08-20       Impact factor: 5.469

8.  Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells.

Authors:  E Paus; A T Myklebust
Journal:  Tumour Biol       Date:  1996

9.  Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100.

Authors:  Neil R Grubb; Catriona Simpson; Roy A Sherwood; Hagosa D Abraha; Stuart M Cobbe; Ronan E O'Carroll; Ian Deary; Keith A A Fox
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

Review 10.  Neuron-specific enolase.

Authors:  E H Cooper
Journal:  Int J Biol Markers       Date:  1994 Oct-Dec       Impact factor: 3.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.